BioHarvest Sciences (BHST) Investor Presentation summary

Strategic vision and technology

• Focuses on sustainable, economical production of patentable plant compounds for health and wellness, using proprietary Botanical Synthesis technology that isolates and multiplies plant cells without growing the whole plant.

• Botanical Synthesis enables consistent, high-potency, non-GMO compounds with lower resource use and cost, protected by 14 granted patents and multiple pending.

• Two growth engines: direct-to-consumer (D2C) wellness products and CDMO services for multiple verticals, including pharma, nutraceuticals, cosmetics, and nutrition.

• AI-driven discovery phase identifies and develops new plant-based compounds, optimizing for efficacy, patentability, and scalability.

Product portfolio and market validation

• Flagship product VINIA® (red grape cell powder) has over $50M in lifetime sales, 65,000+ active users, and strong clinical validation for cardiovascular benefits.

• Product line expanding into hydration, sports drinks, functional coffee/tea, and new plant compounds (olive and pomegranate) with launches planned through 2026.

• Clinical trials show VINIA® increases artery dilation by 70%, boosts nitric oxide by 120%, and reduces ET-1 by 50%.

• Business model is replicable across new plant compounds, with olive and pomegranate products targeting liver, cholesterol, joint, and brain health.

Financial and operational performance

• Q2 2025 revenue reached $8.5M, up 41% year-over-year, with gross profit margin rising to 59.7% from 51.5% a year ago.

• Over $60M in D2C product revenue in the past four years validates market demand and technology.

• Significant operating leverage achieved, with G&A as a percentage of revenue decreasing.

• Investing for growth with a defined path to adjusted EBITDA breakeven by Q4 2025.